LY2584702

製品コードS7698 バッチS769801

印刷

化学情報

Chemical Structure Synonyms N/A Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C21H19F4N7
分子量 445.42 CAS No. 1082949-67-4
Solubility (25°C)* 体外 DMSO (warmed with 50ºC water bath) 4.44 mg/mL (9.96 mM)
Water Insoluble
Ethanol Insoluble
体内 （毎回新しく調製した物を用意してください）
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM.
in vitro

In HCT116 colon cancer cells, LY2584702 inhibits phosphorylation of the S6 ribosomal protein (pS6) with IC50 of 0.1-0.24 μM. [1]

This compound has significant synergistic effects when combined with EGFR inhibitor or with the mTOR inhibitor. [2]
in vivo

LY2584702 (12.5 mg/kg BID), demonstrates significant antitumor efficacy in both U87MG glioblastoma and HCT116 colon carcinoma xenograft models. [1]

プロトコル(参考用のみ)

細胞アッセイ 細胞株 Neuronal cells
濃度 250 nM
反応時間 24 h
実験の流れ

Cells were treated with indicated concentration of this compound for 24 h.
動物実験 動物モデル U87MG glioblastoma and HCT116 colon carcinoma xenograft models
投薬量 12.5 mg/kg BID
投与方法 --

参考

  • https://pubmed.ncbi.nlm.nih.gov/24440085/
  • https://pubmed.ncbi.nlm.nih.gov/24456794/
  • https://pubmed.ncbi.nlm.nih.gov/35508467/

カスタマーフィードバック

Data from [Data independently produced by , , Oncotarget, 2016, 7(25):38451-38466]

Data from [Data independently produced by , , J Immunol, 2016, 197(9):3545-3553]

Data from [Data independently produced by , , Antiviral Res, 2018, 158:13-24]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Amino acid-dependent TSC2 dephosphorylation by lysosome-PP2A regulates mTORC1 signaling transduction [ Life Sci Alliance, 2025, 8(11)e202503206] PubMed: 40897470
CHI3L1/YKL-40 signaling inhibits neurogenesis in models of Alzheimer's disease [ Sci Adv, 2025, 11(29):eadv1492] PubMed: 40680137
mTORC1 restricts TFE3 activity by auto-regulating its presence on lysosomes [ Mol Cell, 2024, S1097-2765(24)00832-3] PubMed: 39486419
The oncogenic lncRNA MIR503HG suppresses cellular senescence counteracting supraphysiological androgen treatment in prostate cancer [ J Exp Clin Cancer Res, 2024, 43(1):321] PubMed: 39676172
Proapoptotic role of CDK1 in overcoming paclitaxel resistance in ovarian cancer cells in response to combined treatment with paclitaxel and duloxetine [ Cancer Cell Int, 2024, 24(1):409] PubMed: 39702300
Duloxetine enhances the sensitivity of non-small cell lung cancer cells to EGFR inhibitors by REDD1-induced mTORC1/S6K1 suppression [ Am J Cancer Res, 2024, 14(3):1087-1100] PubMed: 38590408
Multiplex Protein Imaging through PACIFIC: Photoactive Immunofluorescence with Iterative Cleavage [ ACS Bio Med Chem Au, 2023, 3(3):283-294] PubMed: 37363079
Multiplex Protein Imaging through PACIFIC: Photoactive Immunofluorescence with Iterative Cleavage [ ACS Bio Med Chem Au, 2023, 3(3):283-294] PubMed: 37363079
Control of cell state transitions [ Nature, 2022, 609(7929):975-985] PubMed: 36104561
Direct control of lysosomal catabolic activity by mTORC1 through regulation of V-ATPase assembly [ Nat Commun, 2022, 13(1):4848] PubMed: 35977928

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。